Serial MRI and CSF biomarkers in normal aging, MCI, and AD

Prashanthi D Vemuri, H. J. Wiste, S. D. Weigand, David S Knopman, J. Q. Trojanowski, L. M. Shaw, Matthew A Bernstein, P. S. Aisen, M. Weiner, Ronald Carl Petersen, Clifford R Jr. Jack

Research output: Contribution to journalArticle

108 Citations (Scopus)

Abstract

Objective: To compare the annual change in MRI and CSF biomarkers in cognitively normal (CN), amnestic mild cognitive impairment (aMCI), and Alzheimer disease (AD). Comparisons were based on intergroup discrimination, correlation with concurrent cognitive/functional changes, relationships to APOE genotype, and sample sizes for clinical trials. Methods: We used data from the Alzheimer's Disease Neuroimaging Initiative study consisting of CN, aMCI, and AD cohorts with both baseline and 12-month follow-up CSF and MRI. The annual change in CSF (total-tau [t-tau], Aβ1-42) and MRI (change in ventricular volume) was obtained in 312 subjects (92 CN, 149 aMCI, 71 AD). Results: There was no significant average annual change in either CSF biomarker in any clinical group except t-tau in CN; moreover, the annual change did not differ by clinical group in pairwise comparisons. In contrast, annual increase in ventricular volume increased in the following order, AD > aMCI > CN, and differences were significant between all clinical groups in pairwise comparisons. Ventricular volume increase correlated with concurrent worsening on cognitive/functional indices in aMCI and AD whereas evidence of a similar correlation with change in CSF measures was unclear. The annual changes in MRI differed by APOE ε4 status overall and among aMCI while annual changes in CSF biomarkers did not. Estimated sample sizes for clinical trials are notably less for MRI than the CSF or clinical measures. Conclusions: Unlike the CSF biomarkers evaluated, changes in serial structural MRI are correlated with concurrent change on general cognitive and functional indices in impaired subjects, track with clinical disease stage, and are influenced by APOE genotype.

Original languageEnglish (US)
Pages (from-to)143-151
Number of pages9
JournalNeurology
Volume75
Issue number2
DOIs
StatePublished - Jul 13 2010

Fingerprint

Alzheimer Disease
Biomarkers
Sample Size
Genotype
Clinical Trials
Neuroimaging
Cognitive Dysfunction

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Serial MRI and CSF biomarkers in normal aging, MCI, and AD. / Vemuri, Prashanthi D; Wiste, H. J.; Weigand, S. D.; Knopman, David S; Trojanowski, J. Q.; Shaw, L. M.; Bernstein, Matthew A; Aisen, P. S.; Weiner, M.; Petersen, Ronald Carl; Jack, Clifford R Jr.

In: Neurology, Vol. 75, No. 2, 13.07.2010, p. 143-151.

Research output: Contribution to journalArticle

Vemuri, Prashanthi D ; Wiste, H. J. ; Weigand, S. D. ; Knopman, David S ; Trojanowski, J. Q. ; Shaw, L. M. ; Bernstein, Matthew A ; Aisen, P. S. ; Weiner, M. ; Petersen, Ronald Carl ; Jack, Clifford R Jr. / Serial MRI and CSF biomarkers in normal aging, MCI, and AD. In: Neurology. 2010 ; Vol. 75, No. 2. pp. 143-151.
@article{04fb14878e2e44ae9f6f274cae1bdf9e,
title = "Serial MRI and CSF biomarkers in normal aging, MCI, and AD",
abstract = "Objective: To compare the annual change in MRI and CSF biomarkers in cognitively normal (CN), amnestic mild cognitive impairment (aMCI), and Alzheimer disease (AD). Comparisons were based on intergroup discrimination, correlation with concurrent cognitive/functional changes, relationships to APOE genotype, and sample sizes for clinical trials. Methods: We used data from the Alzheimer's Disease Neuroimaging Initiative study consisting of CN, aMCI, and AD cohorts with both baseline and 12-month follow-up CSF and MRI. The annual change in CSF (total-tau [t-tau], Aβ1-42) and MRI (change in ventricular volume) was obtained in 312 subjects (92 CN, 149 aMCI, 71 AD). Results: There was no significant average annual change in either CSF biomarker in any clinical group except t-tau in CN; moreover, the annual change did not differ by clinical group in pairwise comparisons. In contrast, annual increase in ventricular volume increased in the following order, AD > aMCI > CN, and differences were significant between all clinical groups in pairwise comparisons. Ventricular volume increase correlated with concurrent worsening on cognitive/functional indices in aMCI and AD whereas evidence of a similar correlation with change in CSF measures was unclear. The annual changes in MRI differed by APOE ε4 status overall and among aMCI while annual changes in CSF biomarkers did not. Estimated sample sizes for clinical trials are notably less for MRI than the CSF or clinical measures. Conclusions: Unlike the CSF biomarkers evaluated, changes in serial structural MRI are correlated with concurrent change on general cognitive and functional indices in impaired subjects, track with clinical disease stage, and are influenced by APOE genotype.",
author = "Vemuri, {Prashanthi D} and Wiste, {H. J.} and Weigand, {S. D.} and Knopman, {David S} and Trojanowski, {J. Q.} and Shaw, {L. M.} and Bernstein, {Matthew A} and Aisen, {P. S.} and M. Weiner and Petersen, {Ronald Carl} and Jack, {Clifford R Jr.}",
year = "2010",
month = "7",
day = "13",
doi = "10.1212/WNL.0b013e3181e7ca82",
language = "English (US)",
volume = "75",
pages = "143--151",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Serial MRI and CSF biomarkers in normal aging, MCI, and AD

AU - Vemuri, Prashanthi D

AU - Wiste, H. J.

AU - Weigand, S. D.

AU - Knopman, David S

AU - Trojanowski, J. Q.

AU - Shaw, L. M.

AU - Bernstein, Matthew A

AU - Aisen, P. S.

AU - Weiner, M.

AU - Petersen, Ronald Carl

AU - Jack, Clifford R Jr.

PY - 2010/7/13

Y1 - 2010/7/13

N2 - Objective: To compare the annual change in MRI and CSF biomarkers in cognitively normal (CN), amnestic mild cognitive impairment (aMCI), and Alzheimer disease (AD). Comparisons were based on intergroup discrimination, correlation with concurrent cognitive/functional changes, relationships to APOE genotype, and sample sizes for clinical trials. Methods: We used data from the Alzheimer's Disease Neuroimaging Initiative study consisting of CN, aMCI, and AD cohorts with both baseline and 12-month follow-up CSF and MRI. The annual change in CSF (total-tau [t-tau], Aβ1-42) and MRI (change in ventricular volume) was obtained in 312 subjects (92 CN, 149 aMCI, 71 AD). Results: There was no significant average annual change in either CSF biomarker in any clinical group except t-tau in CN; moreover, the annual change did not differ by clinical group in pairwise comparisons. In contrast, annual increase in ventricular volume increased in the following order, AD > aMCI > CN, and differences were significant between all clinical groups in pairwise comparisons. Ventricular volume increase correlated with concurrent worsening on cognitive/functional indices in aMCI and AD whereas evidence of a similar correlation with change in CSF measures was unclear. The annual changes in MRI differed by APOE ε4 status overall and among aMCI while annual changes in CSF biomarkers did not. Estimated sample sizes for clinical trials are notably less for MRI than the CSF or clinical measures. Conclusions: Unlike the CSF biomarkers evaluated, changes in serial structural MRI are correlated with concurrent change on general cognitive and functional indices in impaired subjects, track with clinical disease stage, and are influenced by APOE genotype.

AB - Objective: To compare the annual change in MRI and CSF biomarkers in cognitively normal (CN), amnestic mild cognitive impairment (aMCI), and Alzheimer disease (AD). Comparisons were based on intergroup discrimination, correlation with concurrent cognitive/functional changes, relationships to APOE genotype, and sample sizes for clinical trials. Methods: We used data from the Alzheimer's Disease Neuroimaging Initiative study consisting of CN, aMCI, and AD cohorts with both baseline and 12-month follow-up CSF and MRI. The annual change in CSF (total-tau [t-tau], Aβ1-42) and MRI (change in ventricular volume) was obtained in 312 subjects (92 CN, 149 aMCI, 71 AD). Results: There was no significant average annual change in either CSF biomarker in any clinical group except t-tau in CN; moreover, the annual change did not differ by clinical group in pairwise comparisons. In contrast, annual increase in ventricular volume increased in the following order, AD > aMCI > CN, and differences were significant between all clinical groups in pairwise comparisons. Ventricular volume increase correlated with concurrent worsening on cognitive/functional indices in aMCI and AD whereas evidence of a similar correlation with change in CSF measures was unclear. The annual changes in MRI differed by APOE ε4 status overall and among aMCI while annual changes in CSF biomarkers did not. Estimated sample sizes for clinical trials are notably less for MRI than the CSF or clinical measures. Conclusions: Unlike the CSF biomarkers evaluated, changes in serial structural MRI are correlated with concurrent change on general cognitive and functional indices in impaired subjects, track with clinical disease stage, and are influenced by APOE genotype.

UR - http://www.scopus.com/inward/record.url?scp=77954706306&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954706306&partnerID=8YFLogxK

U2 - 10.1212/WNL.0b013e3181e7ca82

DO - 10.1212/WNL.0b013e3181e7ca82

M3 - Article

C2 - 20625167

AN - SCOPUS:77954706306

VL - 75

SP - 143

EP - 151

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 2

ER -